Create a free research account to view current pricing and place an order.
Mechanism of action
KPV is a tripeptide derived from alpha-MSH research. It is associated with melanocortin-linked anti-inflammatory signaling, NF-kB modulation, and mucosal/skin inflammation pathway support.
Half-life & pharmacokinetics
Half-life: Short acting.
Human pharmacokinetics are not standardized. Treat exposure as short acting unless compound-specific data or formal formulation labeling indicates otherwise.
Research dosing reference
250-1000 mcg one to two times daily depending on inflammation target.
Dose interpretation (U-100 units)
| Target dose | U-100 units |
|---|---|
| 250 mcg | 5 units |
| 500 mcg | 10 units |
| 1000 mcg | 20 units |
Units are concentration-specific - confirm against your actual reconstitution volume.
Reconstitution & concentration
| Vial | Preferred reconstitution | Final concentration |
|---|---|---|
| 10 mg | 2 mL BAC Water | 0.050 mg/unit |
Injection timing
Daily or split AM/PM depending on protocol objective. Local versus systemic placement should be determined by research design and clinician preference.
Beginner escalation
Start with conservative exposure to evaluate injection-site tolerance and systemic response before increasing or layering additional repair agents.
Side-effect mitigation
Monitor injection tolerance, GI response, fatigue, headache, or unexpected immune/inflammatory changes.
Stack compatibility
Pairs with BPC/TB/GHK-Cu when inflammation is part of the repair target; avoid over-stacking anti-inflammatory agents initially.
Storage & stability
Lyophilized: refrigerated or controlled cool storage. Reconstituted: refrigerated, protected from heat/light, and handled aseptically.
Protocol duration & reassessment
Short-course, tightly controlled protocols are preferred. Reassess immune/inflammatory response before repeating or extending, especially with irritating or immune-active peptides.
Frequently asked questions
What is KPV and how does it work?
KPV is a tripeptide derived from alpha-MSH research. It is associated with melanocortin-linked anti-inflammatory signaling, NF-kB modulation, and mucosal/skin inflammation pathway support.
What is the half-life of KPV?
KPV: Short acting. Human pharmacokinetics are not standardized. Treat exposure as short acting unless compound-specific data or formal formulation labeling indicates otherwise.
How is KPV reconstituted for research?
Preferred reconstitution for the 10 mg vial is 2 mL BAC Water, giving 0.050 mg/unit. Always confirm concentration math before any use. Research use only.
Is KPV FDA approved?
No. KPV is an investigational research-use-only compound - not for human or animal consumption and not FDA approved.
KPV product overview · KPV cost · All research reference · Research guides
External references: Peptide (Wikipedia) · U.S. Food and Drug Administration